We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Miraculins Purchases VeraLight’s Noninvasive Diabetes Screening Technology

By LabMedica International staff writers
Posted on 09 Jul 2013
Print article
Miraculins Inc. (Winnipeg, Canada) has completed the final purchase agreement with VeraLight, Inc. (Albuquerque, NM, USA) on June 28, 2013, to acquire all of the relevant assets, including intellectual property, licenses, and regulatory approvals, inventories, data, and marketing materials, relating to VeraLight’s SCOUT DS technology. The diabetes screening technology noninvasively measures changes in the composition of a person's skin indicative of diabetes.

All of the relevant assets, including intellectual property, licenses, and regulatory approvals, inventories, data, and marketing materials, relating to VeraLight’s SCOUT DS technology, will be acquired by Miraculins in exchange for a combination of cash and Miraculins’ common shares.

The SCOUT DS test utilizes visible light to noninvasively measure changes in a person's skin indicative of prediabetes and type 2 diabetes. The patient places his/her forearm on the portable, tabletop instrument that measures advanced glycation end products in the skin. The SCOUT DS finds more prediabetics faster, easier, and more cost-effectively than alternative world-standard tests such as fasting plasma glucose, oral glucose tolerance, hemoglobin a1c, and finger stick blood glucose.

SCOUT DS tests individuals in 80 seconds without blood draw or the need to fast, and produces immediate results. It is indicated for use for the noninvasive screening of individuals 18 years or older that are at risk for diabetes. SCOUT DS will be sold individually or together with Miraculin's PreVu skin cholesterol Point-of-Care (POC) test, which assists with coronary artery disease risk assessment and detection.

“With diabetes being the fastest growing disease in history, as well as a major risk factor for coronary artery disease, the SCOUT DS along with the PreVu POC test will represent the unparalleled assembly of new, noninvasive tools to assist with the assessment of millions of individuals at risk worldwide,” said Christopher J. Moreau, president and CEO of Miraculins Inc. “This acquisition will provide Miraculins and our distribution network—including the retail pharmacy segment—with another significant competitive edge, while allowing us to move Miraculins closer to its corporate mission of becoming a global leader in the provision of diagnostic tests and risk assessment technologies, including noninvasive screening platforms.”

The SCOUT DS has already received clearance from Health Canada for commercial distribution, has been granted a CE Mark in the European Union, and it is cleared for sale in Mexico. Commercial piloting of the technology has already taken place in Canada, and multiple preliminary distribution channels have also been established or advanced including in countries that may recognize Health Canada and CE regulatory clearances such as Saudi Arabia, Qatar, the United Arab Emirates, India, Jordan, Brazil, Turkey and Kuwait.

Miraculins will seek US marketing clearance for SCOUT DS as soon as possible. In the interim, distribution in the United States of the SCOUT DS system remains limited to investigational use only.

Miraculins is an emerging biotechnology company, which develops and commercializes diagnostic tests.

Related Links:

Miraculins Inc.
VeraLight, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.